Citation:Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, et al 2013

From Cancer Guidelines Wiki

Citation


Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Eur J Cancer 2013 Jul;49(10):2424-32 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23510802.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Optimal molecular profilingVictoria Freemancompleted
Optimal molecular profilingBen Lee-Batescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Optimal molecular profiling